Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:

NCT ID: NCT00735280 Completed - Clinical trials for Coronary Artery Disease

Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI

ISAR-REACT-3A
Start date: August 2008
Phase: Phase 4
Study type: Interventional

The aim of this trial is to evaluate whether a reduction in the heparin dose from 140 to 100 U/kg is associated with a better net clinical outcome in patients undergoing PCI after pretreatment with 600mg clopidogrel

NCT ID: NCT00733460 Completed - Clinical trials for Coronary Artery Disease

A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET

Start date: March 2008
Phase: Phase 1
Study type: Interventional

Safety and dosimetry of BFPETâ„¢ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.

NCT ID: NCT00733174 Recruiting - Clinical trials for Impaired Glucose Tolerance

Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance

Start date: March 2004
Phase: Phase 4
Study type: Interventional

Subjects with impaired glucose tolerance will be randomized to either rosiglitazone or placebo for a 18 month period. The study will look at baseline, 12 month and 18 month data for exercise tolerance, coronary artery calcification and diabetes indicators.

NCT ID: NCT00732953 Completed - Clinical trials for Coronary Artery Disease

Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries

Start date: February 2009
Phase: Phase 2/Phase 3
Study type: Interventional

Percutaneous coronary intervention with stent implantation is limited on the one hand by restenosis due to smooth muscle cell proliferation and on the other hand by stent thrombosis due to incomplete or not sufficient enough endothelialization of stent struts. The Genous stent implantation allows a rapid layer over the stent struts with endothelial progenitor cells allowing a fast endothelialization and probably reducing the risk of stent thrombosis. Local therapy with drug-eluting balloons administering paclitaxel has been shown to reduce restenosis in in-stent restenosis and de-novo lesions in vessels with small reference diameter. The combination of a paclitaxel-eluting balloon and Genous stent implantation may summarized both advantages: a rapid endothelialization limiting the number of stent thrombosis and on the other hand a reduction of smooth muscle cell proliferation minimizing the risk of restenosis with the subsequent need for revascularization.

NCT ID: NCT00731237 Completed - Clinical trials for Coronary Artery Disease

XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery

EXCEED
Start date: October 2008
Phase: N/A
Study type: Observational

This trial is to assess physician-determined XIENCE V® EECSS acute performance, deliverability and resource utilization in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience

NCT ID: NCT00730899 Recruiting - Clinical trials for Coronary Artery Disease

Association Study of Gene Polymorphisms With Cardiac Performance

Start date: May 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether polymorphisms in G protein subunits, namely Galphas and Galphaq, are associated with altered cardiac performance in heart failure patients.

NCT ID: NCT00730132 Completed - Clinical trials for Hypercholesterolemia

Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)

Start date: January 2008
Phase:
Study type: Observational

This study is being performed to evaluate what variants of lipid-lowering therapy are used in Russian clinical practice in coronary heart disease (CHD) patients with hypercholesterolemia in whom the initial statin therapy did not achieve low density lipoprotein-cholesterol (LDL-C) goals. Additionally, the efficacy and safety of all variants of modified lipid-lowering therapy are to be evaluated.

NCT ID: NCT00729040 Completed - Obesity Clinical Trials

Enhancing Adherence by Building Online Communities

Start date: January 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether online peer support will increase adherence to an internet-based pedometer walking program.

NCT ID: NCT00728299 Completed - Clinical trials for Coronary Artery Disease

The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness

Start date: September 2003
Phase: N/A
Study type: Interventional

Increases in carotid artery intima-media thickness (IMT) are correlated with increased risk of stroke and myocardial infarction. The purpose of this study is to assess if pomegranate juice will retard the carotid (IMT) progression rate in men and women who have one or more existing cardiovascular risk factors (current cigarette smoking, hypertension, low HDL-cholesterol, and/or high LDL-cholesterol) upon entrance into the study.

NCT ID: NCT00728156 Completed - Clinical trials for Coronary Artery Disease

Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)

Start date: August 2009
Phase: Phase 4
Study type: Interventional

Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are more likely to have recurring symptoms. Using a novel "clotting chamber" the investigators have shown that patients with diabetes are more likely to develop blood clots. This study will look at the role of different blood thinning medications in patients with diabetes. If successful, the investigators will provide evidence to conduct large clinical studies to look at the role of additional blood thinning medication in reducing heart attacks and strokes in patients with diabetes.